trending Market Intelligence /marketintelligence/en/news-insights/trending/q-zskt_2jxnmxuhv2gaapq2 content esgSubNav
In This List

Novo Nordisk seeks US, EU approval for hemophilia A treatment

Blog

Commercial Banking: June 22nd Edition

Blog

Understanding Loss Given Default A Review of Three Approaches

Blog

Commercial Banking Newsletter June Edition - 2022

Blog

Insight Weekly: US recession outlook; mortgage activity slowdown; climate disclosure push


Novo Nordisk seeks US, EU approval for hemophilia A treatment

Novo Nordisk A/S filed a biologics license application with the US Food and Drug Administration and a marketing authorization application with the European Medicines Agency for N8-GP to treat people with hemophilia A.

Hemophilia A is caused by the genetic deficiency in clotting protein, factor VIII, resulting in increased bleeding, and usually affects males.

N8-GP is an extended half-life factor VIII, which can stay in the bloodstream for a longer duration and thus requires less frequent injections.

The submission is based on the pathfinder clinical trial program which showed that N8-GP reduced bleeding rates among adults, children as well as people undergoing surgery.